Product Details
| Product Name: Aprepitant | CAS No.: 170729-80-3 |
| Min. Order: 1g | Purity: 99.0% |
| Supply Ability: 50kg/month | Release date: 2020/07/22 |
▼
▲
Prodcut name
Aprepitant
Synonyms
mk 0869; 5-[2(R)-[1(R)-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)morpholin-4-ylmethyl]-3,4-dihydro-2H-1,2,4-triazol-3-one
MOQ
1G
CAS No.
170729-80-3 (221350-96-5)
Appearance
white to off white crystalline powder
Molecular Formula
C23H21F7N4O3
Molecular Weight
534.43
Assay
98.0~102.0%
Application
Pharma grade or research purpose
Packing
As per your request
Storage
Preserve in tight,light-resistant containers in a cool place
Remarks
Enterprise standard
Custom synthesis
Available
Supply Ability
50kg/month
Company Profile Introduction
Beijing Yibai Biotechnology Co., Ltd features:
1. Management layer's full experience in factory and skilled technicians followers;
2. 10 years experienced exporting sales team;
3. Independent R&D lab;
4. Two signed long term GMP partnership;
5. Rich resources of plenty idle factories for customized project;
6. High Efficiency working team with consistent path.
You may like
-
CAS:152459-95-5
-
CAS:221350-96-5
-
CAS:1256963-02-6
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $48.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-29 | |
|
VIP1Y
|
Improve Medical Technology(Nanxiong) Co.,Ltd
|
2025-09-26 | ||
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | ||
|
Hebei Chuanghai Biotechnology Co., Ltd
|
2024-11-05 | |||
|
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-09-05 | ||
| $1.90 |
VIP5Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-20 | |
| $20.00 |
Hebei Yanxi Chemical Co., Ltd.
|
2023-11-24 | ||
| $10.00 |
Henan Bao Enluo International TradeCo.，LTD
|
2023-07-13 | ||
| $280.00 |
VIP4Y
|
Hebei Dangtong Import and export Co LTD
|
2023-03-09 | |
|
Changzhou Rokechem Technology Co., Ltd.
|
2022-10-13 |
China- Since: 2018-03-06
- Address: A2011, No.86, Wanxing Road, Changyang, Fangshan District, Beijing, China
INQUIRY